Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979202 | 1.00 | CYP2C9 (0.34) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16979175 | 0.96 | CYP2C9 (0.36) | CYP2C9ALDH1A1LMNAMAPTHTR2A | |
| SCHEMBL16979234 | 0.92 | CYP2C9 (0.34) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL13289848 | 0.88 | CYP2C9 (0.34) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16983256 | 0.86 | CYP2C9 (0.33) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16983557 | 0.86 | CYP2C9 (0.33) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16983515 | 0.85 | CYP2C9 (0.33) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16983269 | 0.85 | CYP2C9 (0.33) | CYP2C9TLR4ALDH1A1LMNAMAPT | |
| SCHEMBL16979151 | 0.83 | CNR2 (0.36) | CYP2C9MAPT | |
| SCHEMBL16979207 | 0.83 | CYP2C9 (0.40) | CYP2C9TLR4ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783481-B2 | Carbonyl derivative, liquid crystal composition containing compound thereof and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | RCC2, RCC1, ROCK2 | CYP2C9 1928/4885TLR4 3606/4885ALDH1A1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.